Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. (REVB) is a clinical-stage biotechnology company pioneering immunologic therapeutics through its proprietary Gemini platform. This centralized news hub provides investors and healthcare professionals with essential updates on the company's inflammatory disease research and clinical developments.
Access timely reports on Revelation Biosciences' therapeutic pipeline including Gemini-SSI (surgical infection prevention), Gemini-AKI (acute kidney injury), and Gemini-CKD (chronic kidney disease) programs. Our curated news collection covers clinical trial milestones, regulatory updates, scientific presentations, and strategic partnerships relevant to TLR4 agonist development.
This resource serves investors tracking the company's progress in inflammation modulation and researchers monitoring PHAD-based therapeutic innovations. Content is rigorously verified to ensure accurate reporting on Revelation Biosciences' clinical-stage developments without speculative commentary.
Bookmark this page for streamlined access to REVB's latest press releases, peer-reviewed study findings, and material event disclosures. Check regularly for updates on the Gemini formulation's advancement through clinical testing phases and related biopharmaceutical industry developments.
Revelation Biosciences Inc. (NASDAQ: REVB) reported its first quarter 2022 financial results, noting significant progress in corporate initiatives. The company completed a merger with Petra Acquisition, Inc. and raised $7.7 million through PIPE financing. Cash reserves increased to $7.2 million from $1.3 million in Q4 2021, enabling operations funding through 2022. However, the net loss rose to $6.6 million ($0.47 per share), up from $2.6 million ($0.42 per share) in Q1 2021, primarily due to clinical study expenses.
Revelation Biosciences Inc. (NASDAQ: REVB) announced ongoing enrollment in the phase 1b CLEAR study for its lead therapeutic candidate, REVTx-99b, targeting allergic rhinitis, with top-line data expected in the second half of 2022. The company is also in discussions for diagnostic partnerships related to its REVDx-501 rapid home-use diagnostic tool for respiratory viral infections. An investor conference call is scheduled for April 7, 2022, to discuss these developments further.
Revelation Biosciences Inc. (NASDAQ: REVB) announced interim results from its Phase 2b viral challenge study evaluating intranasal REVTx-99a for H3N2 influenza prevention. The study, conducted in Belgium with 30 healthy participants, reported no serious adverse events. However, REVTx-99a failed to meet its primary endpoint, showing no statistically significant difference from the placebo. CEO James Rolke expressed disappointment but emphasized ongoing commitment to other candidates like REVTx-99b for allergic rhinitis management and REVDx-501, a home diagnostic test for respiratory viruses.
Revelation Biosciences (NASDAQ: REVB) announced the completion of dosing and enrollment for its Phase 2b viral challenge study, RVL-VRL01, aimed at evaluating the efficacy of intranasal REVTx-99a for preventing H3N2 influenza in healthy adults. Primary endpoint analysis is expected early Q2 2022, with final data to follow later that quarter. The study aims to reduce influenza viral load, which correlates with symptom severity. Future studies for REVTx-99a may include SARS-CoV-2 and other respiratory viruses.
Revelation Biosciences Inc. (NASDAQ: REVB) announced that CEO James Rolke will present a corporate overview at the 2022 Virtual Growth Conference from March 28-30, 2022. The company focuses on developing immunologic-based therapies for disease prevention and treatment, including its lead candidate REVTx-99a, designed to combat respiratory viruses like SARS-CoV-2 and influenza. Additionally, Revelation is developing diagnostic solutions such as REVDx-501 for home use to detect respiratory infections. For details, visit www.RevBiosciences.com.
Revelation Biosciences Inc. (NASDAQ: REVB) has completed enrollment and dosing in its Phase 2b viral challenge study (RVL-VRL01) to assess the efficacy of intranasal REVTx-99 against H3N2 influenza in healthy participants. This trial aims to evaluate key metrics such as viral load reduction and symptom duration. Initial primary endpoint data is expected by early Q2 2022. REVTx-99 targets a broad immune response, with plans to extend development to other respiratory viruses, including SARS-CoV-2.
Revelation Biosciences Inc. (NASDAQ: REVB) announced that CEO James Rolke will present a corporate overview at the 34th Annual Roth Conference from March 13-15, 2022, at The Ritz Carlton, Laguna Niguel in California. Rolke's presentation is scheduled for March 15, 2022, at 8:00 a.m. PT in Blue – Salon 2. A live webcast will be available on the company's website, and a replay will be accessible for 30 days post-event. Revelation is focused on developing immunologic-based therapies, with its lead candidate REVTx-99 targeting respiratory viral infections.
Revelation Biosciences Inc. (NASDAQ: REVB) will present a corporate overview at the BIO CEO & Investor Conference on February 14, 2022, at 10:45 a.m. EST in New York City. CEO James Rolke will host one-on-one meetings throughout the event. The company is focused on developing immunologic therapies, including REVTx-99 for respiratory virus infections and REVTx-200 for enhanced vaccination immunity. Revelation is also advancing REVDx-501, a rapid home diagnostic for respiratory viruses. For details, visit RevBiosciences.com.
Revelation Biosciences Inc. (NASDAQ: REVB) has announced a definitive agreement to sell 1,293,126 shares of common stock at $3.00 per share, raising approximately $7.76 million before expenses. The company will also issue warrants for 2,586,667 common shares and pre-funded warrants for 1,239,541 shares. Proceeds will be allocated to advancing its clinical pipeline and for general working capital. The deal is expected to close upon meeting all conditions, including stock exchange approval. Roth Capital Partners is the exclusive placement agent for this offering.
Revelation Biosciences Inc. (NASDAQ: REVB) announced the enrollment of 15 patients in a Phase 2b viral challenge study for the intranasal therapy REVTx-99, targeting H3N2 influenza prevention. This study, conducted in Belgium, aims to evaluate REVTx-99's efficacy against respiratory viral infections by activating an innate immune response. The company expects topline data by Q2 2022.
REVTx-99 may also be applicable for SARS-CoV-2 and other respiratory viruses, addressing a significant need for new therapeutic options amid ongoing viral challenges.
FAQ
What is the current stock price of Revelation Biosciences (REVB)?
What is the market cap of Revelation Biosciences (REVB)?
